Mineralys Therapeutics (MLYS) Cash from Operations (2022 - 2026)

Mineralys Therapeutics has disclosed Cash from Operations across 5 years of filings, most recently posting 39471000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 39471000.0, up 13.23% year-over-year; the trailing twelve-month figure through Mar 2026 was 136400000.0 (up 29.2% YoY), and the FY2025 annual result was 142416000.0, up 14.37% from the prior year.
• Cash from Operations came in at 39471000.0 for Q1 2026 at Mineralys Therapeutics, down from 37916000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5469000.0 in Q2 2022 to a low of 66843000.0 in Q4 2024.
• The 5-year median for Cash from Operations is 28800000.0 (2025), against an average of 26976176.47.
• Across the five-year window, Cash from Operations sank 272.76% in 2023 and jumped 43.28% in 2025, its largest moves.
• Mineralys Therapeutics' Cash from Operations stood at 10186000.0 in 2022, then slumped by 184.52% to 28981000.0 in 2023, then slumped by 130.64% to 66843000.0 in 2024, then surged by 43.28% to 37916000.0 in 2025, then decreased by 4.1% to 39471000.0 in 2026.
• The last three Cash from Operations figures came in at 39471000.0 (Q1 2026), 37916000.0 (Q4 2025), and 28800000.0 (Q3 2025), per Business Quant data.